Form 4: UTHR CEO Executes Stock Options, Sells Shares

United Therapeutics CEO Martine Rothblatt exercised stock options and sold common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (UTHR), reported transactions involving common stock.
• The transactions occurred on October 9, 2025, and October 10, 2025, under a pre-arranged 10b5-1 trading plan established on May 2, 2025.
• On October 9, 2025, Rothblatt acquired 4,000 shares of common stock by exercising stock options at $120.26 per share.
• On the same day, Rothblatt disposed of 4,000 shares of common stock through three separate sales at weighted average prices of $445.25, $449.5825, and $451.24.
• On October 10, 2025, Rothblatt acquired another 4,000 shares of common stock by exercising stock options at $120.26 per share.
• Also on October 10, 2025, Rothblatt disposed of 4,000 shares of common stock through two separate sales at weighted average prices of $442.9584 and $445.2767.
• The 10b5-1 plan covers a tranche of 294,000 stock options expiring March 15, 2026, and will continue until the earlier of exhaustion of this tranche or December 31, 2025.
• Following these transactions, Rothblatt directly owns 130 shares of common stock and indirectly owns 544,393 shares through various family trusts and spouse holdings.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it involves insider selling, it's a pre-arranged plan, which mitigates negative perceptions. The significant profit realized by the insider from exercising options at a low price and selling at a high price is a positive for the individual, but the filing itself does not reflect directly on the company's operational performance or future prospects.

Positives

• The reporting person exercised stock options at a significantly lower price ($120.26) compared to the sale prices (ranging from $442.9584 to $451.24), indicating a substantial profit on the transactions.
• The transactions were conducted under a pre-arranged 10b5-1 trading plan, which demonstrates a structured approach to managing equity holdings and reduces concerns about opportunistic insider selling.

Negatives

• The sale of common stock by a key executive, even under a pre-arranged plan, represents a reduction in direct insider ownership.

Future Outlook

The pre-arranged 10b5-1 trading plan is set to continue until the earlier of the exhaustion of a tranche of 294,000 stock options that expire on March 15, 2026, or December 31, 2025.

Management Comments

• The exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on May 2, 2025.

Industry Context

This filing is a routine insider transaction report and does not provide information directly related to broader industry trends or competitive landscape.

Related Party Transactions

• Shares are held indirectly by spouse and in various family trusts where the Reporting Person and/or immediate family members are beneficiaries or have shared investment power.

Stakeholder Impact

• Shareholders: Minor, routine dilution from option exercise, followed by open market sales. The pre-arranged nature of the sales minimizes market surprise.
• Employees: No direct impact mentioned.

Next Steps

• Continuation of the 10b5-1 trading plan until the earlier of the exhaustion of the 294,000 stock option tranche or December 31, 2025.

Key Dates

Keywords

United Therapeutics, UTHR, Martine Rothblatt, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, Common Stock, Executive Compensation